PD-0325901 ( DrugBank: PD-0325901 )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
34	神経線維腫症	2

34. 神経線維腫症

---

臨床試験数 : 137 /  薬物数 : 213 - (DrugBank : 76) / 標的遺伝子数 : 87 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03962543 (ClinicalTrials.gov)	September 6, 2019	12/4/2019	MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas	A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity	Plexiform Neurofibroma;Neurofibromatosis Type 1 (NF1)	Drug: Mirdametinib (PD-0325901) oral capsule or dispersible tablet	SpringWorks Therapeutics, Inc.	NULL	Active, not recruiting	2 Years	N/A	All	114	Phase 2	United States
2	NCT02096471 (ClinicalTrials.gov)	June 2014	12/3/2014	MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1	A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas	Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN	Drug: PD-0325901	University of Alabama at Birmingham	NULL	Completed	16 Years	N/A	All	19	Phase 2	United States